KC
NKTR icon

Kepos Capital’s Nektar Therapeutics NKTR Stock Holding History

Kepos Capital’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-3,847
Closed -$1.9M – 381
2018
Q4 		$1.9M Sell
3,847
-3,416
-47% -$2.06M 0.15% 156
2018
Q3 		$6.64M Buy
7,263
+6,440
+783% +$5.5M 0.34% 53
2018
Q2 		$603K Hold
823
– – 0.03% 266
2018
Q1 		$1.31M Buy
+823
New +$1.06M 0.08% 160

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Kepos Capital's NKTR Position: Q1 2019 in Review

Kepos Capital sold out of Nektar Therapeutics (NKTR) in Q1 2019, closing a stake of 3,847 shares — an estimated $1.9M sold.

Kepos Capital first reported a position in NKTR in Q1 2018 and held it in 4 quarters. The position peaked at $6.64M in Q3 2018. 349 funds tracked by Wall St. Rank hold NKTR as of Q1 2019.

  • Kepos Capital reported no remaining Nektar Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Kepos Capital sold 3,847 Nektar Therapeutics shares in Q1 2019, an estimated $1.9M.
  • Kepos Capital first reported a position in Nektar Therapeutics in Q1 2018 and held it in 4 quarters.
  • Kepos Capital's Nektar Therapeutics position peaked at $6.64M in Q3 2018.
  • 349 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2019.

Based on Kepos Capital's 13F filing for Q1 2019, filed 13 May 2019.